- Home
- CRBP vs BEAT Comparison
CRBP vs BEAT Comparison
Compare CRBP & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- BEAT
- Stock Information
- Founded
- CRBP 2009
- BEAT 2015
- Country
- CRBP United States
- BEAT United States
- Employees
- CRBP N/A
- BEAT N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- CRBP Health Care
- BEAT Technology
- Exchange
- CRBP Nasdaq
- BEAT Nasdaq
- Market Cap
- CRBP 73.4M
- BEAT 59.0M
- IPO Year
- CRBP N/A
- BEAT 2021
- Fundamental
- Price
- CRBP $7.34
- BEAT $1.81
- Analyst Decision
- CRBP Strong Buy
- BEAT Buy
- Analyst Count
- CRBP 10
- BEAT 1
- Target Price
- CRBP $53.56
- BEAT $8.00
- AVG Volume (30 Days)
- CRBP 114.6K
- BEAT 62.0K
- Earning Date
- CRBP 05-06-2025
- BEAT 05-13-2025
- Dividend Yield
- CRBP N/A
- BEAT N/A
- EPS Growth
- CRBP N/A
- BEAT N/A
- EPS
- CRBP N/A
- BEAT N/A
- Revenue
- CRBP N/A
- BEAT N/A
- Revenue This Year
- CRBP N/A
- BEAT N/A
- Revenue Next Year
- CRBP $150.00
- BEAT N/A
- P/E Ratio
- CRBP N/A
- BEAT N/A
- Revenue Growth
- CRBP N/A
- BEAT N/A
- 52 Week Low
- CRBP $4.64
- BEAT $1.45
- 52 Week High
- CRBP $61.90
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- CRBP 52.51
- BEAT 57.12
- Support Level
- CRBP $7.05
- BEAT $1.50
- Resistance Level
- CRBP $7.62
- BEAT $1.70
- Average True Range (ATR)
- CRBP 0.49
- BEAT 0.13
- MACD
- CRBP -0.02
- BEAT 0.02
- Stochastic Oscillator
- CRBP 42.65
- BEAT 77.50
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.